The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.
Cantarini, L., Lopalco, G., Vitale, A., Caso, F., Lapadula, G., Iannone, F., Galeazzi, M., Rigante, D., Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant, <<INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES>>, 2015; 2015 (Maggio): 473-475. [doi:10.1111/1756-185X.12521] [http://hdl.handle.net/10807/68774]
Autori: | |
Titolo: | Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1111/1756-185X.12521 |
Data di pubblicazione: | 2015 |
Abstract: | The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript. |
Lingua: | Inglese |
Rivista: | |
Citazione: | Cantarini, L., Lopalco, G., Vitale, A., Caso, F., Lapadula, G., Iannone, F., Galeazzi, M., Rigante, D., Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant, <<INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES>>, 2015; 2015 (Maggio): 473-475. [doi:10.1111/1756-185X.12521] [http://hdl.handle.net/10807/68774] |
Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.